Sirolimus Coated Balloon in BTK Treatment makes a bold presence at VEITH 2022 – Lights up NY Times Square, NASDAQ


    TAMPA, Fla., Dec. 2, 2022 /PRNewswire/ -- VEITH 2022 witnessed a surge of supporting clinical data for Sirolimus Coated Balloon in the treatment of Below-the-Knee (BTK) disease. Concept Medical Inc. hosted a lunch symposium titled 'Sirolimus Coated Balloon in PAD Treatment: Choice of The Future' which explored the utility of Sirolimus Coated Balloon treatment in PAD. The session was chaired by Prof. Sahil Parikh, co-moderated by Prof. Edward Choke and Prof. Aloke Finn with interesting presentations by Prof. Ulf Teichgräber and Prof. Francesco Liistro.

     

    Congratulations Global Principal Investigator A/Prof Edward Choke, Sengkang General Hospital, Singapore
    Congratulations Global Principal Investigator A/Prof Edward Choke, Sengkang General Hospital, Singapore

     

    One of the highlights of the session was the follow up data of clinical outcomes of the XTOSI Trial. XTOSI (Xtreme Touch Sirolimus coated PTA balloon) is a single arm trial for Sirolimus Coated Balloon (MagicTouch PTA) investigating the clinical use and safety of the device in the treatment of infrainguinal Peripheral Arterial Disease (PAD). This prospective, premarket, non-randomized, all comers single-arm study, led by PI Prof. Edward Choke enrolled 50 patients to study the Magic Touch PTA Sirolimus Coated Balloon (Concept Medical Inc.) at Sengkang General Hospital, Singapore. It is the world's first trial of Sirolimus Coated Balloon for BTK disease and has the longest follow up data. While the primary endpoints already suggested promising patency and safety at 6 months, the data presented at VEITH 2022 shed more light on the longer-term efficacy and the safety of the Sirolimus Coated Balloon.

    Prof. Edward Choke, further presented updates on the FUTURE SFA and FUTURE BTK RCTs, a family of randomised trials set to enrol 279 and 219 patients respectively, against standard uncoated balloon in 2:1 fashion and are ongoing in Singapore, Taiwan and Thailand. FUTURE BTK has already completed 25% of its enrolment target, credits to the principal investigators of all sites involved.

    Sirolimus Coated Balloon for PAD continues its march, knocking on the doors of the US and lighting up the iconic New York Times Square with a dazzling display of the study results of XTOSI and the recruitment status of the FUTURE BTK.

    Watch the complete session to know more about exciting clinical data: https://youtu.be/2xokmMuhzuc

    China Expert network
    PR Newswire is the premier global provider of news release distribution and multimedia platforms that enable marketers, corporate communicators, sustainability officers, public affairs and investor relations officers to leverage content to engage with all their key audiences. Having pioneered the commercial news distribution industry since 1954, PR Newswire today provides end-to-end solutions to produce, optimize and target content – from rich media to online video to multimedia – and then distribute content and measure results across traditional, digital, mobile and social channels. Combining the world's largest multi-channel distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire powers the stories of organizations around the world. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and the Asia-Pacific region, and is a Cision company.

    RELATED NEWS